 Aldeyra Therapeutics, Inc. Nasdaq: ALDX Aldeyra, a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced block sales of an aggregate of 4,580,361 shares of common stock to Perceptive Advisors, LLC and Avidity Partners Management LP, two leading healthcare-focused investment funds, under Aldeyras previously announced at-the-market offering program. The shares were sold for a price of 4.25 per share. Aggregate gross proceeds, before deducting commissions, were approximately 19.5 million. The sales completed Aldeyras previously disclosed at-the-market offering program and no further sales will be made under this program. Jefferies, LLC served as sales agent under the at-the-market offering program. 